Brief: Acurx Pharmaceuticals Reports Fourth Quarter Results
16/03/2023 11:03
March 16 (Reuters) - Acurx Pharmaceuticals Inc ACXP.O :
* ACURX PHARMACEUTICALS, INC. REPORTS FOURTH QUARTER AND
FULL YEAR
2022 RESULTS AND PROVIDES BUSINESS UPDATE
* ACURX PHARMACEUTICALS INC - ENDED YEAR, WITH CASH TOTALING
$9.1
MILLION COMPARED TO $13.0 MILLION AS OF DECEMBER 31, 2021
* ACURX PHARMACEUTICALS INC - NET LOSS OF $3.3 MILLION OR
$0.28
PER DILUTED SHARE FOR THREE MONTHS ENDED DECEMBER 31, 2022
Source text for Eikon: ID:nPn6BrJlNa
Further company coverage: ACXP.O
Recent news on Acurx Pharmaceuticals
See all newsBrief: Acurx Pharmaceuticals Receives FDA Conditional Acceptance
Acurx Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 loss widens on higher R&D costs
Acurx Pharmaceuticals Inc expected to post a loss of 38 cents a share - Earnings Preview
Brief: FDA Provides Further Regulatory Guidance To Acurx Pharmaceuticals For The Ibezapolstat Clinical Development Program